| Dr Jeffrey Ross Embrey, MD | |
|
10 Medical Park Dr, Asheville, NC 28803-2493 | |
| (828) 210-1792 | |
| Not Available |
| Full Name | Dr Jeffrey Ross Embrey |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 42 Years |
| Location | 10 Medical Park Dr, Asheville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063429132 | NPI | - | NPPES |
| EM080P081 | Other | TX | BLUE CROSS |
| 038067701 | Medicaid | TX |
| Facility Name | Location | Facility Type |
|---|---|---|
| Margaret R Pardee Memorial Hospital | Hendersonville, NC | Hospital |
| Memorial Mission Hospital And Asheville Surgery Ce | Asheville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mountain Area Pathology Pa | 2567490832 | 12 |
News Archive
According to a new study, smokers are at least 6 times more likely to develop gum disease than non-smokers.
Wellstar International, Inc., has announced that it has entered into a financing agreement with JMJ Financial to provide the Company with an expected $1.2 million dollars in operational funding over the eighteen months. Details of the financing were contained in the Company's Form 8-K filing with the Securities and Exchange Commission on October 9, 2009.
New World Health Organization data to be published in this week's edition of the Lancet will shed new light on two leading causes of pneumonia, the world's leading killer of children under age 5, both globally and within specific countries.
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
› Verified 8 days ago
| Entity Name | Mountain Area Pathology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386600054 PECOS PAC ID: 2567490832 Enrollment ID: O20050728000314 |
News Archive
According to a new study, smokers are at least 6 times more likely to develop gum disease than non-smokers.
Wellstar International, Inc., has announced that it has entered into a financing agreement with JMJ Financial to provide the Company with an expected $1.2 million dollars in operational funding over the eighteen months. Details of the financing were contained in the Company's Form 8-K filing with the Securities and Exchange Commission on October 9, 2009.
New World Health Organization data to be published in this week's edition of the Lancet will shed new light on two leading causes of pneumonia, the world's leading killer of children under age 5, both globally and within specific countries.
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey Ross Embrey, MD Po Box 17147, Chapel Hill, NC 27516-7147 Ph: () - | Dr Jeffrey Ross Embrey, MD 10 Medical Park Dr, Asheville, NC 28803-2493 Ph: (828) 210-1792 |
News Archive
According to a new study, smokers are at least 6 times more likely to develop gum disease than non-smokers.
Wellstar International, Inc., has announced that it has entered into a financing agreement with JMJ Financial to provide the Company with an expected $1.2 million dollars in operational funding over the eighteen months. Details of the financing were contained in the Company's Form 8-K filing with the Securities and Exchange Commission on October 9, 2009.
New World Health Organization data to be published in this week's edition of the Lancet will shed new light on two leading causes of pneumonia, the world's leading killer of children under age 5, both globally and within specific countries.
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
› Verified 8 days ago
Joseph Patrick Sleater, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Pathology Dept, Asheville, NC 28801 Phone: 828-253-0762 Fax: 828-254-4892 | |
Harold Chalmers Poston Jr., MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Pathology Dept, Asheville, NC 28801 Phone: 828-253-0763 | |
Richard L Landau, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 509 Biltmore Ave, Pathology Dept, Asheville, NC 28801 Phone: 828-253-0763 | |
Doreen C Griswold, MD Pathology Medicare: Medicare Enrolled Practice Location: 1100 Tunnel Rd, Asheville, NC 28805 Phone: 828-298-7911 | |
Stacey Lynn Neal, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Pathology Dept, Asheville, NC 28801 Phone: 828-253-0763 | |
Meryl Levya Goldstein, MD PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-253-0762 Fax: 828-254-4892 |